House Dust Allergy BRITISH 777 objective test, but the difficulty here is that asthmatics usually take a variety of drugs, which may be bronchodilators, antibiotics, or sedatives. Since most patients do not know what purpose their various medicines serve, no attempt was made to discriminate between the number of tablets of each variety, though as a test of progress only the bronchodilators would be expected to reflect fluctuations in the severity of asthma. The number of occasions on which an aerosol was used is probably a more reliable criterion of progress. Because of these difficulties in setting up objective criteria of progress, the expiratory peak flow is the only quantitative observation free of bias in this study. The limitations of making this measurement only once a month were appreciated, but the difficulties of repeating it more frequently proved to be insuperable. The variability of observations in asthmatics from one day to another is well known, and for this reason no attempt was made to analyse in any detail the month-by-month changes in peak flow. A simple method of recording the trend of these six measurements as improvement or deterioration was thought to be the most that could be extracted from these data. The uncertainty of the observation is not presented in an attempt to throw doubt on the negative result of this trial, but merely to stress a problem inherent in the study of a disease in which the state of the patient varies from day to day and in which most of the observations reflecting these changes cannot be translated into objective measurements.
Another source of uncertainty is that house dust extract cannot be standardized by chemical tests or biological assay, so that its composition may vary from one batch to another. Which of its many components causes asthma has not been established, and it is possible that the material used in this study was deficient in extract of mites or some other relevant antigen. This doubt applies with equal force to other commercially available house dust extracts and will not be resolved until these antigens are identified.
Patients who were given advice on house dust control in their homes did not fare any better than those who did not receive such advice. Possible reasons are either that the amount of house dust is immaterial, or that the patients did not carry out their instructions, or that these instructions were not effective in reducing the dust below the critical level. Nothing was known about the habitat of the house dust mite at the time, and the possible importance of mattress dust was therefore not appreciated (Cunnington, 1967) . It was also found in retrospect that some patients who had not been explicitly advised were nevertheless exercising some control over house dust, acting on common sense or on advice received from sources outside this study.
An observation not foreseen in the design of the study is that physicians vary in their clinical judgement of what they will accept as pure house dust allergy. The criteria of diagnosis were closely defined in the protocol, but what eventually decided whether the history given by patients incriminated house dust alone or other antigens as well was the opinion of the physician. When the reason for the large differences in the number of entries was discussed it became clear that some physicians regard pure house dust allergy as rare and think that it is nearly always accompanied by allergies to other inhaled antigens, particularly pollen, while others readily diagnose pure house dust allergy among their patients.
An interesting sidelight on the attitude of patients to clinical trials is that so many of them were willing to take part in this study. The details of the treatment were explained with scrupulous fairness so that each patient clearly understood that the 15 injections he was to receive were at best of an extract of doubtful efficacy and at worst of a substance unlikely to have any therapeutic value at all. In spite of this explanation only 20 of the 116 patients approached declined to take part. This is a suitable place to acknowledge the Research Committee's indebtedness to those patients who accepted the inconvenience and discomfort of this investigation. , 1968, 3, 777-780 Summary: Significant variations in the incidence of depression and loss of libido were found with the various types of oral contraceptives. The highest incidence occurred with strongly progestogenic compounds (especially with those containing a small amount of oestrogen) which have high monoamine oxidase activity for most of the cycle. The lowest incidence was found with the strongly oestrogenic sequential regimens which have weak monoamine oxidase activity for most of the cycle. Introduction Mears and Grant (1962) , Pullen (1962) , and Goldzieher et al. (1962) reported that premenstrual tension improved in women taking progestogenic/oestrogenic oral contraceptives. Mears and Grant (1962) also reported changes in libido which they suggested might be due to psychological factors. However, it became clear that depressive changes were more troublesome with some products than with others. It was therefore decided to study the effect of the various types of oral contraceptives on the histochemistry of a selected group of enzymes in the endometrium. Monoamine progestogenic (break-through bleeding 2%) it also contains a high dose of mestranol and has a low incidence of depression and loss of libido, whereas Volidan (megestrol acetate 4 mg.+ethinyloestradiol 0.05 mg.) is less progestogenic (break-through bleeding 10%) but contains a low dose of ethinyloestradiol and has a high incidence of depressive change.
Other mood changes noted were tiredness, irritability, aggression, and increased libido. These could not be related to hormone balance but may be influenced by vascular changes. Aggression was particularly noticeable with norethisterone acetate 1 mg. and ethinyloestradiol 0.075 mg., which had a marked effect on the development of both arterioles and sinusoids in the endometrium. Premenstrual tension, which was a common complaint before the trial, especially in older women, almost invariably improved. Only a few women discontinued the tablets because of mood changes in the early cycles, but over the period of the trial 40 % of those withdrawing for side-effects had at least one mood complaint.
Histochemical Results Fig. 1 shows the activities of the three enzymes according to the day of the cycle. In the untreated groups (I and VI) the late secretory phase is also indicated.
Untreated Cycle
Alkaline phosphatase activity was strongest in the late proliferative phase in the glandular and superficial epithelium, decreased in the latter half of the cycle, and disappeared in the late secretory phase. Activity was considered strong when more than two-thirds of the epithelium showed activity, moderate when about half the epithelium stained, and weak when less than a third showed evidence of activity. Alkaline phos- phatase was also seen in capillary and arteriolar endothelium throughout the cycle, but arteries showed little or no activity. Acid phosphatase showed a more generalized activity in both epithelium and stroma. Early in the cycle there was weak staining of all elements, in mid-cycle staining became heavier in the epithelial cells, while in the later secretory phase there was a further increase of staining in the epithelium. These three degrees of activity were regarded as weak, moderate, and strong respectively.
Monoamine oxidase activity in the first half of the cycle was seen as dark granules or fine droplets scattered in the stroma and epithelium with no selective vascular staining. In the late secretory phase a purple-blue colour developed diffusely in the glandular epithelium, especially the luminal border. As a result of parallel biochemical studies by Southgate et al. (1967) it was found that the diffuse blue stain was associated with high monoamine oxidase activity in vitro and the granular stain with weak activity. Biopsies from 20 untreated and 24 treated patients in this series were also examined biochemically for monoamine oxidase activity; the results corresponded with the histochemical findings in each case, ranging from 1,000 to 20,000 units.
Enzyme activity in the cycles one month before and one to six months after treatment (Fig. 1, VI) M.,, therapy, normal activity was found during the third recovery month. Grant (1967) described the histology of the normal and oral-contraceptive-treated endometrium.
Treated Cycles
Strongly Progestogenic Combined Tablets (Break-through Bleeding 0.3%).-The high dose of progestogen allows only a short growth and early secretory phase from day 7 to 11, which is followed by a prolonged post-secretory phase or atrophic phase, when the small glands have a single layer of low columnar cells. The enzyme pattern showed changes typical of a late secretory phase as early as day 12 (Fig. 1, II) . Alkaline phosphatase was weak from day 10 and acid phosphatase strong from day 12. Monoamine oxidase was strong from day 12 even from very small fragments of atrophic endometrium. The overall incidence of depression and loss of libido on these preparations was 28% with ethinyloestradiol but only 17% when combined with larger doses of mestranol.
Sequential Tablets (Break-through Bleeding 0-5%).-By contrast the strong oestrogen stimulation in the sequential regimens produces accentuated growth and early secretory phases and allows no definite secretory changes as late as day 26 (Fig.  1, III ). There was a low monoamine oxidase level throughout the cycle. The incidence of depression and loss of libido on these preparations was 6%.
Weakly Progestogenic Combined Tablets (Break-through Bleeding 4-40%).-These have more prolonged proliferative and early secretory phases, the length of the latter being proportional to the incidence of break-through bleeding. A tablet with a 4% incidence has a modified early secretory phase from days 8 to 12, while one with 40% incidence of break-through bleeding may be secretory from days 10 to 20. (a) Containing 0.05-0.09 mg. Ethinyloestradiol: An intermediate picture was seen in this group with a gradual decrease in alkaline phosphatase and early increase in acid phosphatase activity (Fig. 1, IV) . The post-secretory low columnar or cuboidal glands showed a weak, moderate, or strong monoamine oxidase activity from day 17 onwards.
(b) Containing 0.075-0.1 mg. Mestranol: Alkaline phosphatase was stronger and acid phosphatase weaker during the cycle than with the corresponding ethinyloestradiol tablets. Though most specimens were from Ovulen and Lyndiol 2.5 (break-through bleeding 4%) which produce a post-secretory atrophic endometrium from day 13 onwards, only two biopsies showed a strong monoamine oxidase activity (Fig. I, V) . The day 24 specimen giving a strong reaction was from the Ovulentreated endometrium of a woman complaining of loss of libido. The other strong reaction was given after several months' continuous therapy with Lyndiol 2.5, when the patient was complaining of depression and abdominal distension: cyclic therapy, discontinued because of menstrual headaches, was then restarted at the patient's request.
Discussion
In the normal cycle there is a dramatic rise in the monoamine oxidase activity of the endometrium in the late secretory phase. At this time endogenous oestrogen levels fall and premenstrual tension is common, especially among older women. With a strongly progestogenic combined oral contraceptive tablet the rise in endometrial monoamine oxidase occurs early in the cycle at day 12, at which time the woman is receiving constant amounts of exogenous oestrogen. If the amount of oestrogen is low some women may notice a depressant effect on mood or libido. Though a strongly progestogenic combined tablet such as Lyndiol has strong monoamine oxidase activity early in the cycle, the high dose of oestrogen in the tablet seems to protect against the depressant effect. However, Ferin (1966, personal communication) found that some ovariectomized women taking Lyndiol became depressed and treated them with monoamine oxidase inhibitors. With the strongly oestrogenic sequential regimens the amount of oestrogen is high, the monoamine oxidase activity low, and fewer women complain of depression. With the intermediate compounds monoamine oxidase varies in activity and may even be weak in post-secretory glands.
It is interesting, in view of our finding in women, that Michael et al. (1967) showed that progesterone inhibited sexual receptivity in female rhesus monkeys. As the endometrium is especially sensitive to variations in oestrogens and progestogens the changes in monoamine oxidase activity may reflect similar changes occurring in other sensitive areas of the body such as the hypothalamus. Cyclic changes in the rat hypothalamus have been reported by Kuwabara et al. (1967) , who found that monoamine oxidase and biogenic amine activity reached a maximum at pro-oestrus. In women, plasma monoamine oxidase has been found to double at the end of the cycle, and significantly higher values were recorded in amenorrhoeic women (Klaiber et al., 1967) . These findings support the hypothesis that progestogenic stimulation causes generalized changes in monoamine oxidase metabolism which may be a factor in the occurrence of depression and loss of libido in susceptible women. Kane et al. (1967) described mood and behavioural disturbances in women who were using a variety of oral contraceptives, while Daly et al. (1967) reported two cases of psychosis associated with the use of sequential regimens. In our series many women had mood disturbances and vascular side-effects at the same time. It seems possible that susceptibility to mood changes may be affected by vascular reactivity (Grant, 1968 
